Superbugs blasted by aerosols

November 29, 2012
Superbugs blasted by aerosols
Nano-sized antibiotics delivered via aerosol could be the answer to treating superbugs that are resistant to other treatments.

(Medical Xpress)—Blasting superbugs with tiny nano-sized antibiotics delivered via powder aerosol may be a faster, safer and cheaper way of treating respiratory infectious diseases such as pneumonia or cystic fibrosis, claim University of Sydney pharmacy researchers.

Dr Qi (Tony) Zhou, academic researcher in the Faculty of Pharmacy and recipient of this year's 'Peter Doherty - Australian Biomedical Fellowship' awarded by the National Health and Medical Research Council, says respiratory infectious diseases are a major health problem for Australians.

Each year, respiratory tract infections cost Australian taxpayers more than $150 million in direct costs and considerably more in indirect costs due to absenteeism and loss of productivity. Upper and infections account for almost seven million visits to GPs each year in Australia.

With the incidence of respiratory infection on the rise and superbugs now being blamed for the increase, it is imperative that researchers find better treatments to combat these emerging villains, says Dr Zhou.

"At the moment, the most common way of treating is with oral or . Due to antibiotic resistance, treatment using aggressive antibacterial agents is becoming more and more necessary. But these salvage medicines can cause dire side effects for patients such as severe diarrhea, or even irreversible organ damage," Dr Zhou says.

"The antibiotic agent, Colistin for example, is often a last-line offensive against some superbugs. But its can cause neuron or kidney damages in up to 50 percent of patients."

Dr Zhou's team will develop tiny nano-sized antibiotics that will be packaged in inhalers. The team includes world-leader of respiratory drug delivery, Professor Hak-Kim Chan, also from the Faculty of Pharmacy, infectious disease experts at Monash University and a top nanoscience team based at Princeton University, USA.

"These new inhaled nanomedicines will target the antibiotics directly at the respiratory tract. Ultimately they will be easier to carry and operate and have a more rapid drug-action," says Professor Hak-Kim Chan.

"The new inhaled nanoantibiotic therapy will be pivotal in the fight to reduce drug resistance and adverse effects for combating respiratory superbugs."

Explore further: Short antibiotic courses safer for breathing-tube infections in children

Related Stories

A world without antibiotics?

April 7, 2011

Imagine a world without antibiotics. Common infections are life threatening. Pneumonia, urinary tract infections and venereal diseases are incurable. Cancer chemotherapies do not exist. The life expectancy for Canadian men ...

Recommended for you

Zika in fetal brain tissue responds to a popular antibiotic

November 30, 2016

Working in the lab, UC San Francisco researchers have identified fetal brain tissue cells that are targeted by the Zika virus and determined that azithromycin, a common antibiotic regarded as safe for use during pregnancy, ...

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

Flu forecasts successful on neighborhood level

November 30, 2016

Scientists at Columbia University's Mailman School of Public Health developed a computer model to predict the onset, duration, and magnitude of influenza outbreaks for New York City boroughs and neighborhoods. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.